NEW YORK, Aug. 1, 2017 /Weed Wire/ — Fiorello Pharmaceuticals, Inc., a pharmaceutical company focused on aiding patients with significant, painful and life-threatening conditions, is proud to announce that it has been selected as a Registered Organization in the expansion of New York State’s Medical Marijuana Program.
Fiorello Pharmaceuticals will operate a medical marijuana cultivation and manufacturing facility in Glenville, New York and dispense products in four locations across New York State. The dispensaries will be situated in New York, Nassau, Monroe and Saratoga counties.
The company’s four dispensaries will be operated by specially trained pharmacists. The pharmacists will counsel certified patients and their caregivers, and dispense appropriate medicine to them. Patients are required to obtain a certification for medical marijuana from registered health care professionals to treat chronic pain, and symptoms of multiple sclerosis, Parkinson’s disease, cancer, epilepsy, ALS, HIV/AIDS, and other diseases.
Fiorello Pharmaceuticals will leverage the leadership team’s strong pharmaceutical expertise with over 80 years of combined pharmaceutical executive experience. The company plans to employ a pharmaceutical approach to product development and commercialization that will enable Fiorello to establish a new standard in the medical marijuana industry nationwide.
“Our mission is to deliver the highest-quality, cutting-edge medicinal marijuana products to patients who will benefit from this important medicine. We pride ourselves on truly caring for patients and treating them with the compassion and respect they deserve.” said Eric Sirota, Co-CEO, Fiorello Pharmaceuticals. “Improved patient access to regulated medical marijuana and increased educational outreach to practitioners and patients will result in better health outcomes and help ensure that patients receive the most comprehensive, integrated health care.”
“Fiorello is committed to bringing the most innovative, highly differentiated products into the marketplace. Our experienced team will be incorporating best practices from diverse industries into all phases of our business,” said Susan Yoss, Co-CEO, Fiorello Pharmaceuticals. “Our goal is to build an efficient operation that delivers superior medicine to patients at a more affordable price.”
“We applaud the Governor and the New York State Legislature and Department of Health for showing their support for the pharmaceutical benefits of medical marijuana,” said Judith Tytel, General Counsel, Fiorello Pharmaceuticals. “The Department of Health has worked tirelessly over the last few years to deliver New Yorkers a best-in-class medical marijuana program and to ensure that the program will be able to serve the unmet needs of patients.”
The company will be led by a team of senior executives with decades of experience in the pharmaceutical, finance and consumer product industries. Eric Sirota, and Judith Tytel are accomplished pharmaceutical executives and Susan Yoss is a seasoned executive with over 25 years of experience in regulated consumer and financial industries, including more than a decade at Seagram.
Both Eric Sirota and Judith Tytel held senior executive roles for over twenty years at Pfizer Inc.
Former Pfizer CEO and Chairman Henry McKinnell said, “I am pleased to support the endeavors of two former Pfizer senior leaders, Eric Sirota and Judith Tytel, now senior leaders at Fiorello Pharmaceuticals. They are continuing the important work of improving the lives of underserved patients, as they did under my leadership at Pfizer.”
Fiorello Pharmaceuticals has signed strategic alliances with leading medical marijuana companies, including The Clinic. The Clinic, which has been in operation since 2009, currently operates three cultivation centers and five dispensaries in Colorado as well as medical marijuana operations in Illinois and Nevada.
Fiorello Pharmaceuticals’ work will be enhanced by the advice of exemplary Scientific Advisory and Business Advisory Boards. Both Boards include members who are prominent figures in the healthcare industry.
“Fiorello Pharmaceuticals has the same desire to improve patient care as we do at Long Island University School of Pharmacy,” said John Pezzuto Dean, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, and a Scientific Advisory Board member. “Fiorello Pharmaceuticals is an ideal partner, and we look forward to working closely with them to support pharmacist, provider and patient education and explore potential scientific research including observational studies to make lives better for patients suffering from cancer or other debilitating diseases.”
Fiorello Pharmaceuticals will immediately begin to build its state-of-the-art medical marijuana manufacturing facility in Glenville, creating a number of management, research, and technology jobs in the Capital Region. Additional employees will work in its dispensaries across New York State
“Fiorello Pharmaceuticals has developed a comprehensive strategy and built the right team to deliver innovation to the medical marijuana industry,” said Sirota. “We look forward to improving the health and well-being of people across New York.”
“We have spent the last several years preparing for our launch and maintaining critical strategic alliances. We are ready to start servicing the people of New York State,” said Yoss
About Fiorello Pharmaceuticals
The mission of Fiorello Pharmaceuticals, Inc. is to provide patients suffering from debilitating and life-threatening illnesses with compassionate service and access to high-quality medical marijuana delivered by trained medical professionals. Fiorello aspires to advance scientific understanding, clinical care, and patient education by incorporating medical and pharmaceutical industry best practices into research, development, and education. The name “Fiorello” — Italian for “little flower” — honors legendary New York City Mayor Fiorello H. LaGuardia, who maintained a deep commitment to medical science and the benefits of medical marijuana.